| |
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities. 
|
|
Today’s Big NewsJul 17, 2024 |
|
September 25-27, 2024 | Philadelphia, PA Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Secure your pass today! 
|
|
| By Angus Liu Bayer has claimed a second pivotal trial win for its blockbuster-to-be androgen receptor inhibitor Nubeqa, looking to reach the entire space of metastatic hormone-sensitive prostate cancer. |
|
|
|
By James Waldron Eyeing up ways to keep the money flowing into 2026, the CRISPR-focused company has decided that the preclinical CAR-NK research needs to go—along with 12% of Caribou’s workforce. |
By Conor Hale J&J MedTech put up $7.96 billion in revenue, below analysts’ expectations for the division, to equal a 2.2% reported gain compared to the second quarter of last year. |
By Kevin Dunleavy German pain relief specialist Grünenthal is investing more than 80 million euros ($87 million) to update its two manufacturing facilities in South America. It is the largest outlay the company has dedicated to a manufacturing project in more than 30 years. |
|
Wednesday, August 7, 2024 | 10am ET / 7am PT Demand for safe, cost-effective RNA manufacturing is increasing. Knowing how to effectively streamline processes and choose the right partners are critical to success. Join us as we explore the latest strategies and solutions to meet today’s increasing demands for safety and cost-effectiveness. Register now. 
|
|
By Nick Paul Taylor Roche’s $2.7 billion bet on Carmot Therapeutics has delivered another early win. Participants in a phase 1 trial lost 7.3% of their body weight after taking Carmot’s oral GLP-1 prospect for four weeks, suggesting the candidate can hold its own against rival molecules from the likes of Eli Lilly and Pfizer. |
By Conor Hale Grail, now split from Illumina, is nearing the finish line in its 140,000-participant NHS study, while enrolling over 35,000 patients in the U.S. |
By Zoey Becker The drugmaker plans to grow it its workforce at the site to 2,600, making it the largest of Sanofi's four global capacity centers, according to reports. |
By Andrea Park Novo Nordisk, the maker of weight management drugs Wegovy and Saxenda, has previously outlined a “mission to defeat obesity” by digging into its underlying biological causes, seeking to reduce stigma and, in tandem with both of those efforts, encouraging doctors and patients to view it as a disease to be treated, rather than something that can be reversed through lifestyle changes alone. |
By Nick Paul Taylor Roche’s Genentech has scuttled its SHP2 inhibitor pact, returning the rights to Relay Therapeutics after plowing more than $120 million into the alliance. The action is the latest in a series of terminations of SHP2 deals. |
By Kevin Dunleavy For the second time in 15 months, the FDA has rejected Orexo’s OX124 (naloxone), a nasal spray rescue treatment for opioid overdoses. In a complete response letter, the agency identified two issues with the application, including one which was “unexpected,” the Swedish drug delivery specialist said in a release. |
By James Waldron Aslan Pharmaceuticals had bold ambitions to challenge immunology blockbuster Dupixent, but now the cash-strapped biotech has run out of road. |
By Andrea Park The “Biomarker, Education, Awareness and Testing (BEAT) Lung Cancer” campaign is focused on increasing awareness about biomarker testing and lung cancer screening options across the U.S. and education about why the tests are important, especially among the Black community. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “Podnosis,” Fierce Healthcare’s Anastassia Gliadkovskaya explores the topic of inequities in maternal and infant health and what one nonprofit is doing to increase transparency and accountability. |
|
|---|
|
|
|
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now. 
|
|
Whitepaper In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more. Sponsored by: Lonza |
Whitepaper The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
Whitepaper In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers. Sponsored by: Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
